Discovery of Novel Natural Product-Based PDE4 Inhibitors for Ischemic Stroke Treatment without Emetogenicity at Ultra-High Doses
- 30 January 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 3037-3061
Abstract
Phosphodiesterase-4 (PDE4) inhibitors show potential for treating ischemic stroke, but are often constrained by emesis or low blood-brain barrier (BBB) permeability. To overcome these challenges, this paper developed novel PDE4 inhibitors via AI-driven structural evolution of natural antistroke products and identified the Phthalide derivative B05 as a PDE4 inhibitor exhibiting excellent selectivity (selectivity index > 420), favorable pharmacological properties (F = 15.5%), and good BBB permeability. Significantly, B05 did not induce vomiting at ultrahigh doses (60 mg/kg), a significant advantage over conventional PDE4 inhibitors. B05 protected neuronal cells from oxygen-glucose deprivation and reoxygenation-induced injury. Additionally, in the middle cerebral artery occlusion and reperfusion model, B05 significantly reduced infarct volume, preserved BBB integrity, attenuated cerebral edema, inhibited astrocyte and microglial activation, prevented ischemia-induced neuronal apoptosis, and improved poststroke motor function and cognitive performance. These findings support the potential of B05 as a promising candidate for the treatment of ischemic stroke.Keywords
Funding Information
- National Natural Science Foundation of China (82504927)
- National Natural Science Foundation of China (82574227)
- Natural Science Foundation of Guangdong Province (2023A1515110921)
- Natural Science Foundation of Guangdong Province (2024A1515011307)
This publication has 33 references indexed in Scilit:
- Neuroprotective mechanisms of microglia in ischemic stroke: a review focused on mitochondriaMolecular Biology Reports, 2025
- A novel PDE4 inhibitor ZX21011 alleviates neuronal apoptosis by decreasing GSK3β-mediated Drp1 Ser616 phosphorylation in cerebral ischemia reperfusionChemico-Biological Interactions, 2025
- Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous systemBiomedicine & Pharmacotherapy, 2024
- Inhibition of phosphodiesterase 4 attenuates aquaporin 4 expression and astrocyte swelling following cerebral ischemia/reperfusion injuryGlia, 2024
- Blood–Brain Barrier Rescue by Roflumilast After Transient Global Cerebral Ischemia in RatsNeurotoxicity Research, 2023
- Apremilast exerts protective effects on stroke outcomes and blood–brain barrier (BBB) dysfunction through regulating Rho‐associated protein kinase 2 expressionBrain and Behavior, 2022
- Ameliorative role of rolipram, PDE-4 inhibitor, against sodium arsenite–induced vascular dementia in ratsEnvironmental Science and Pollution Research, 2021
- Endovascular thrombectomy and intra-arterial interventions for acute ischaemic strokeCochrane Database of Systematic Reviews, 2021
- FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β/ β-catenin signaling pathwayBiochemical Pharmacology, 2019
- The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusionBrain Research Bulletin, 2018